Antiphospholipid antibodies in convalescent plasma of donors recovered from mild COVID-19 infection.
Vox Sang
; 118(7): 517-522, 2023 Jul.
Article
em En
| MEDLINE
| ID: mdl-37191363
ABSTRACT
BACKGROUND AND OBJECTIVES:
Passive immunization by the infusion of convalescent plasma (CP) obtained from patients who have recently recovered from COVID-19, thus having antibodies to severe acute respiratory syndrome coronavirus 2, is a potential strategy to reduce the severity of illness. A high prevalence of antiphospholipid antibodies (APLA) in patients with COVID-19 has been reported during the pandemic, raising a concern whether the use of CP could increase the risk of thrombosis in transfused patients. We aimed to evaluate the prevalence of APLA in COVID-19 CP (CCP) in order to assess the potential prothrombotic influence of transfused CCP to COVID-19 patients. MATERIALS ANDMETHODS:
We studied the prevalence of APLA in 122 CCP samples collected from healthy donors who recovered from mild-COVID-19 at two time periods September 2020-January 2021 (defined as 'early period' samples) and April-May 2021 (defined as 'late period' samples). Thirty-four healthy subjects unexposed to COVID-19 were used as controls.RESULTS:
APLA were present in 7 of 122 (6%) CCP samples. One donor had anti-ß2-glycoprotein 1(anti-ß2GP1) IgG, one had anti-ß2GP1 IgM and five had lupus anticoagulant (LAC) using silica clotting time (SCT), all in 'late period' donors. In the control group, one subject had anti-ß2GP1 IgG, two had LAC using dilute Russell viper venom time (dRVVT) and four had LAC SCT (both LAC SCT and LAC dRVVT in one subject).CONCLUSION:
The low prevalence of APLA in CCP donors reassures the safety of CCP administration to patients with severe COVID-19.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Síndrome Antifosfolipídica
/
COVID-19
Tipo de estudo:
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Vox Sang
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Israel